Table 2.
Study | Region | Study Design | N | Mean Age | In-Hospital | Discharge | F/U | %Morality | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASA | ACE-I/ARB | Statin | BB | Reperfusion | ASA | ACE-I/ARB | Statin | BB | |||||||
ACCEPT (106) | Brazil | Registry | 2,485 | 63 | 0.97 | 0.68 | 0.91 | 0.80 | 0.88* | NR | NR | NR | NR | 30-Day | 1.6 |
ACCESS (116) | Algeria, Argentina, Brazil, Colombia, Dominican Republic, Ecuador, Egypt, Guatemala, Iran, Jordan, Kuwait, Lebanon, Mexico, Morocco, Saudi Arabia, South Africa, Tunisia, United Arab Emirates, Venezuela | Registry | 12,068 | 59.2 | 0.93 | 0.78 | 0.94 | 0.78 | 0.28 | 0.90 | 0.75 | 0.89 | 0.76 | 12 months | 7.3 |
Aga Khan University Hospital, Nairobi (101) | Nairobi, Kenya | Registry | 111 | 64 | NR | NR | NR | NR | 0.38 | NR | NR | NR | NR | In-Hospital | 8.1 |
Brazilian Registry of Acute Coronary Syndromes (RBSCA) (100) | Brazil | Registry | 2,693 | 63 | 0.95 | 0.70 | 0.77 | 0.77 | 0.643 | NR | NR | NR | NR | In-Hospital | 5.5 |
BRIDGE-ACS (177)◆) | Brazil | Randomized Trial | 548 | 62 | 0.958 | NR | 0.729 | NR | NR | 0.928 | 0.761 | 0.86 | 0.817 | 30-Day | 8.4 |
CRACE (108) | China | Registry | 1,301 | 63 | 0.98 | 0.82 | 0.74 | 0.98 | 0.64 | NR | NR | NR | NR | In-Hospital | 4 |
CREATE (130) | India | Registry | 20,937 | 58 | 0.979** | 0.568 | 0.52 | 0.59 | 0.104 | NR | NR | NR | NR | 30-Day | 6.7 |
DEMAT (118) | India | Registry | 1,565 | 58 | 0.96 | NR | 0.93 | 0.79 | 0.67 | 0.94 | 0.66 | 0.88 | 0.79 | 30-Day | 2.1 |
Euro Heart Survey 2009 AMI Snapshot (107) ♓ | Armenia, Bosnia-Herzegovinia, Bulgaria, Croatia, Czech Republic, Georgia, Hungary, Kazakhstan, Kosovo, Macedonia, Moldova, Poland, Romania, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Ukraine | Cross-Sectional Survey | 1,329 | 64 | 0.96 | 0.86 | 0.92 | 0.84 | 0.62 | 0.92 | 0.85 | 0.92 | 0.84 | In-Hospital | 9 |
Gulf RACE-2 (109) | Bahrain, Saudi Arabiam Qatar, Oman, United Arab Emirates, Yemen | Registry | 7,930 | 57 | 0.98 | 0.76 | 0.95 | 0.74 | 0.18 | 0.93 | 0.78 | 0.91 | 0.79 | 12 months | 12 |
Kerala ACS Registry (98) | Kerala, India | Registry | 25,748 | 60 | 0.93 | 0.28 | 0.70 | 0.66 | 0.33 | 0.76 | 0.26 | 0.70 | 0.63 | In-Hospital | 3.9 |
OASIS-2 (95) | Bangladesh, China, India, Lithuania, Russia, Maldives, Slovenia, Ukraine | Registry | 4,615 | 60.7 | 0.95 | NR | NR | 0.67 | NR | NR | NR | NR | NR | 24 months | 9.5 |
PURE (119,120) ❖ | Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, India, Iran, Malaysia, Poland, Pakistan, South Africa, Sweden, Turkey, United Arab Emirates, Zimbabwe | Prospective Cohort | 153,966 | 57 | NA | NA | NA | NA | NA | 0.21 | 0.16 | 0.09 | 0.17 | NR | NR |
RENASICA II (99) | Mexico | Registry | 8,600 | 62 | 0.88 | 0.71 | 0.14 | 0.51 | 0.51 | NR | NR | NR | NR | 30-Day | 10 |
TACSR (113) | Thailand | Registry | 9,373 | NR | 0.95 | 0.63 | 0.80 | 0.62 | 0.37 | NR | NR | NR | NR | In-Hospital | 12.6 |
TRACS (114) | Thailand | Registry | 2,007 | 64 | 0.99 | 0.71 | 0.94 | 0.62 | 0.48 | NR | NR | NR | NR | 12-Months | 17.7 |
UAE-ACS Registry (110) | United Arab Emirates | Registry | 1,842 | 51 | 0.95 | 0.70 | 0.93 | 0.81 | 0.814*** | 0.92 | 0.68 | 0.90 | 0.82 | In-Hospital | 1.7 |
WHO-PREMISE (121) | Brazil, Egypt, India, Indonesia, Iran, Pakistan, Russia, Sri Lanka, Tunisia, Turkey | Cross-Sectional Survey | 10,000 | 59 | NA | NA | NA | NA | NA | 0.821 | 0.398 | 0.298 | 0.481 | NA | NA |
WHO-SAGE (128) | China, Ghana, India, Mexico, Russia, South Africa | Prospective Cohort | 47,443 | 44 | NA | NA | NA | NA | NA | NR | NR | NR | NR | NR | NR |
BRIDGE-ACS (177) data from control arm only.
Euro Heart Study data from Central and Eastern regions only
PURE study ages for CHD only, proportions for CHD in LMICs only.
STEMI patients only;
PCI + CABG;
Any antiplatelet agents;
Fibrinolytics & CABG & deferred PCI;
STEMI with LBBB patients only
NA = not applicable; NT = not reported